Want to see SNN full AI Analyst Report?
SNN Stock Chart & Stats
$32.96
-$0.18(-0.73%)
At close: 4:00 PM EST
$32.96
-$0.18(-0.73%)
Day’s Range― - ―
52-Week Range$28.56 - $38.79
Previous CloseN/A
Volume262.39K
Average Volume (3M)482.36K
Market Cap
$13.04B
Enterprise Value$16.99K
Total Cash (Recent Filing)$557.00M
Total Debt (Recent Filing)$3.33B
Price to Earnings (P/E)20.9
Beta0.50
Next Earnings
Aug 04, 2026EPS Estimate
0.94Next Dividend Ex-DateN/A
Dividend Yield2.56%
Share Statistics
EPS (TTM)1.46
Shares Outstanding421,208,800
10 Day Avg. Volume593,629
30 Day Avg. Volume482,356
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)2.69
Price to Sales (P/S)2.30
P/FCF Ratio16.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.32Price Target Upside-1.94% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.21
Revenue Forecast (FY)$6.57B
Bulls Say, Bears Say
Bulls Say
Strengthening Free Cash FlowMaterial, multi-year FCF improvement demonstrates the business now generates durable operating cash to fund R&D, targeted M&A, buybacks and dividends without relying on new financing. Strong cash conversion enhances strategic optionality and supports execution of the RISE investment and return plans over the medium term.
Innovation-led Product MomentumHigh share of growth from recent launches and sustained pipeline activity indicate structural competitive advantage. New platforms (robotics, wound therapy, orthopaedic systems) drive recurring consumable sales and ASC adoption, supporting resilient mid-term revenue CAGR and higher procedure-based share gains.
Margin Recovery And Operating LeverageMeaningful margin expansion reflects cost savings, manufacturing optimization and pricing leverage. Stable high gross margins plus enterprise cost programs suggest sustainable operating profitability that can support improved ROIC and fund reinvestment, making earnings less vulnerable to moderate volume swings.
Bears Say
Persistent LeverageModerate, unchanged leverage limits financial flexibility for larger bolt-on M&A or aggressive buybacks if margins deteriorate. While adjusted net debt/EBITDA is manageable, failure to delever alongside earnings growth increases vulnerability to cyclic slowdowns or elevated restructuring costs over the medium term.
Regulatory Reimbursement Risk (Skin Substitutes)Permanent reimbursement cuts structurally shrink a wound-care subsegment's revenue and margins. Even with offsetting cost-savings, sustained pricing pressure can reduce long-term unit economics, constrain margin upside in Advanced Wound Management and force reallocation of commercial investment over several years.
China Volume-Based Procurement ImpactValue-based procurement in China has structurally compressed pricing and volumes, causing a lasting reduction in regional revenue and incremental profit pressure. Given the scale of prior sales and ongoing procurement programs, this represents a persistent market-access risk that can cap growth contribution from a large, high-potential geography.
SNN FAQ
What was Smith & Nephew Snats’s price range in the past 12 months?
Smith & Nephew Snats lowest stock price was $28.55 and its highest was $38.79 in the past 12 months.
What is Smith & Nephew Snats’s market cap?
Smith & Nephew Snats’s market cap is $13.04B.
When is Smith & Nephew Snats’s upcoming earnings report date?
Smith & Nephew Snats’s upcoming earnings report date is Aug 04, 2026 which is in 15 days.
How were Smith & Nephew Snats’s earnings last quarter?
Smith & Nephew Snats released its earnings results on Mar 02, 2026. The company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.155 by $0.025.
Is Smith & Nephew Snats overvalued?
According to Wall Street analysts Smith & Nephew Snats’s price is currently Overvalued.
Does Smith & Nephew Snats pay dividends?
Smith & Nephew Snats pays a Semiannually dividend of $0.482 which represents an annual dividend yield of 2.56%. See more information on Smith & Nephew Snats dividends here
What is Smith & Nephew Snats’s EPS estimate?
Smith & Nephew Snats’s EPS estimate is 0.94.
How many shares outstanding does Smith & Nephew Snats have?
Smith & Nephew Snats has 421,208,800 shares outstanding.
What happened to Smith & Nephew Snats’s price movement after its last earnings report?
Smith & Nephew Snats reported an EPS of $1.18 in its last earnings report, beating expectations of $1.155. Following the earnings report the stock price went down -3.088%.
Which hedge fund is a major shareholder of Smith & Nephew Snats?
Currently, no hedge funds are holding shares in SNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Snats Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.32 (-1.94% Downside)
$32.32 (-1.94% Downside)
Blogger Sentiment
Bullish
SNN Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 418.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.53%
12-Months-Change
Fundamentals
Return on Equity
2.56%
Trailing 12-Months
Asset Growth
0.99%
Trailing 12-Months
Company Description
Smith & Nephew Snats
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
SNN Stock 12 Month Forecast
Average Price Target
$32.32
▼(-1.94% Downside)
Technical Analysis
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
0.31% Mutual Funds
0.85% Other Institutional Investors
98.58% Public Companies and
Individual Investors









